HIGHBuilt-inPipeline
DurAVR® THV System
“10-K Item 1A: 'our lead product, DurAVR® THV System, is undertaking clinical trials designed to provide the primary clinical evidence'”
AVR · Concentration risk · 10-K extracted
Anteris Technologies Global Cor (AVR) concentration risks
Updated
The most significant concentration Anteris Technologies Global Cor discloses is DurAVR® THV System, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Anteris Technologies Global Cor’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Anteris Technologies presents a single, clearly structural concentration: the company's lead product, the DurAVR® THV System, is undertaking clinical trials designed to provide the primary clinical evidence for its approval and commercialization. With no other disclosed customer, geographic, or supplier concentration in the filing, the entire near-term investment case rests on this one product's clinical progress. That is a structural rather than idiosyncratic exposure — it defines the addressable business itself rather than reflecting an isolated counterparty or regional shock, since the company does not yet appear to have a diversified commercial base to fall back on. For an educated investor, this single concentration is effectively the whole story: clinical trial outcomes for the DurAVR® THV System are the dominant variable that could move the verdict in either direction, and there is no offsetting diversification disclosed elsewhere in the filing to cushion a setback.
For the engine’s reasoning on AVR’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Instruments & Supplies
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ANGO | AngioDynamics, Inc. | 2 | 1 | 0 | 3 |
| ATRC | AtriCure, Inc. | 1 | 1 | 1 | 3 |
| ATR | AptarGroup, Inc. | 1 | 1 | 0 | 2 |
| ALGN | Align Technology, Inc. | 1 | 0 | 0 | 1 |
| AVR● | Anteris Technologies Global Cor | 1 | 0 | 0 | 1 |
| AVTR | Avantor, Inc. | 1 | 0 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.